AAPL312.60+3.97 (+1.29%) ▲|ABBV254.95-6.12 (-2.34%) ▼|ABT95.61+0.21 (+0.22%) ▲|ACN136.44-0.91 (-0.66%) ▼|ADBE218.35-1.37 (-0.62%) ▼|AMAT594.76-8.29 (-1.37%) ▼|AMD552.99+35.17 (+6.79%) ▲|AMGN366.97-7.18 (-1.92%) ▼|AMT161.82-4.21 (-2.54%) ▼|AMZN244.12+1.45 (+0.60%) ▲|AVGO373.81+13.36 (+3.71%) ▲|AXP356.11+4.15 (+1.18%) ▲|BA234.49+8.00 (+3.53%) ▲|BAC59.90+1.17 (+1.98%) ▲|BKNG181.03-3.53 (-1.91%) ▼|BLK1,011.66+15.93 (+1.60%) ▲|BMY56.70-1.43 (-2.46%) ▼|BNY149.93+3.31 (+2.25%) ▲|BRK-B506.64-1.14 (-0.22%) ▼|C143.87+3.90 (+2.79%) ▲|CAT969.80+6.27 (+0.65%) ▲|CL93.39-1.74 (-1.83%) ▼|CMCSA23.38-0.41 (-1.72%) ▼|COF206.50+1.38 (+0.67%) ▲|COP103.57-1.16 (-1.11%) ▼|COST950.25-1.42 (-0.15%) ▼|CRM165.61-0.50 (-0.30%) ▼|CSCO113.98+1.29 (+1.14%) ▲|CVS102.09-2.64 (-2.52%) ▼|CVX168.14-1.06 (-0.63%) ▼|DE635.71+14.44 (+2.32%) ▲|DHR193.65-4.28 (-2.16%) ▼|DIS97.42-2.08 (-2.09%) ▼|DUK126.01-3.59 (-2.77%) ▼|EMR141.58+2.53 (+1.82%) ▲|FDX309.93-3.07 (-0.98%) ▼|GD376.96+3.42 (+0.92%) ▲|GE378.70+1.65 (+0.44%) ▲|GEV1,152.23+39.12 (+3.51%) ▲|GILD129.61-1.66 (-1.26%) ▼|GM77.86+1.86 (+2.45%) ▲|GOOG364.90+8.72 (+2.45%) ▲|GOOGL366.46+6.55 (+1.82%) ▲|GS1,055.07+34.07 (+3.34%) ▲|HD350.66-7.24 (-2.02%) ▼|HON231.18+1.32 (+0.57%) ▲|IBM299.49+9.97 (+3.44%) ▲|INTC122.20+1.85 (+1.54%) ▲|INTU272.14-3.21 (-1.17%) ▼|ISRG432.83+6.82 (+1.60%) ▲|JNJ259.29-3.75 (-1.43%) ▼|JPM337.87+4.90 (+1.47%) ▲|KO82.97-1.18 (-1.40%) ▼|LIN540.52-6.12 (-1.12%) ▼|LLY1,202.56-11.35 (-0.94%) ▼|LMT537.70-8.21 (-1.50%) ▼|LOW223.77-3.73 (-1.64%) ▼|LRCX350.20-1.21 (-0.34%) ▼|MA533.20-6.20 (-1.15%) ▼|MCD279.47-1.16 (-0.41%) ▼|MDLZ59.17-1.74 (-2.86%) ▼|MDT83.06-0.13 (-0.16%) ▼|META600.29+17.39 (+2.98%) ▲|MMM159.16-1.28 (-0.80%) ▼|MO71.89-0.83 (-1.13%) ▼|MRK126.79-2.77 (-2.14%) ▼|MS222.08+8.15 (+3.81%) ▲|MSFT386.74-3.75 (-0.96%) ▼|MU984.75+9.19 (+0.94%) ▲|NEE87.48-0.86 (-0.97%) ▼|NFLX76.02-1.63 (-2.10%) ▼|NKE43.34-0.76 (-1.71%) ▼|NOW107.91+1.59 (+1.50%) ▲|NVDA195.55+0.72 (+0.37%) ▲|ORCL143.79+3.52 (+2.51%) ▲|PEP143.29-0.93 (-0.64%) ▼|PFE23.73-0.59 (-2.43%) ▼|PG149.31-2.10 (-1.39%) ▼|PLTR132.54+3.24 (+2.51%) ▲|PM184.76+2.49 (+1.37%) ▲|QCOM186.48+10.23 (+5.80%) ▲|RTX201.38+2.13 (+1.07%) ▲|SBUX102.11-2.16 (-2.07%) ▼|SCHW100.61+3.61 (+3.72%) ▲|SO96.00-1.98 (-2.02%) ▼|SPG224.99-1.07 (-0.47%) ▼|T20.59+0.01 (+0.02%) ▲|TMO517.55-5.89 (-1.13%) ▼|TMUS181.79+4.27 (+2.41%) ▲|TSLA419.77+26.32 (+6.69%) ▲|TXN303.50+10.42 (+3.56%) ▲|UBER72.43-2.00 (-2.69%) ▼|UNH418.20-7.16 (-1.68%) ▼|UNP282.58+0.33 (+0.12%) ▲|UPS110.02-0.65 (-0.58%) ▼|USB62.84+1.11 (+1.79%) ▲|V357.23-4.90 (-1.35%) ▼|VZ42.08-0.48 (-1.13%) ▼|WFC87.46+1.95 (+2.28%) ▲|WMT110.65-1.19 (-1.06%) ▼|XOM136.50-0.59 (-0.43%) ▼|AAPL312.60+3.97 (+1.29%) ▲|ABBV254.95-6.12 (-2.34%) ▼|ABT95.61+0.21 (+0.22%) ▲|ACN136.44-0.91 (-0.66%) ▼|ADBE218.35-1.37 (-0.62%) ▼|AMAT594.76-8.29 (-1.37%) ▼|AMD552.99+35.17 (+6.79%) ▲|AMGN366.97-7.18 (-1.92%) ▼|AMT161.82-4.21 (-2.54%) ▼|AMZN244.12+1.45 (+0.60%) ▲|AVGO373.81+13.36 (+3.71%) ▲|AXP356.11+4.15 (+1.18%) ▲|BA234.49+8.00 (+3.53%) ▲|BAC59.90+1.17 (+1.98%) ▲|BKNG181.03-3.53 (-1.91%) ▼|BLK1,011.66+15.93 (+1.60%) ▲|BMY56.70-1.43 (-2.46%) ▼|BNY149.93+3.31 (+2.25%) ▲|BRK-B506.64-1.14 (-0.22%) ▼|C143.87+3.90 (+2.79%) ▲|CAT969.80+6.27 (+0.65%) ▲|CL93.39-1.74 (-1.83%) ▼|CMCSA23.38-0.41 (-1.72%) ▼|COF206.50+1.38 (+0.67%) ▲|COP103.57-1.16 (-1.11%) ▼|COST950.25-1.42 (-0.15%) ▼|CRM165.61-0.50 (-0.30%) ▼|CSCO113.98+1.29 (+1.14%) ▲|CVS102.09-2.64 (-2.52%) ▼|CVX168.14-1.06 (-0.63%) ▼|DE635.71+14.44 (+2.32%) ▲|DHR193.65-4.28 (-2.16%) ▼|DIS97.42-2.08 (-2.09%) ▼|DUK126.01-3.59 (-2.77%) ▼|EMR141.58+2.53 (+1.82%) ▲|FDX309.93-3.07 (-0.98%) ▼|GD376.96+3.42 (+0.92%) ▲|GE378.70+1.65 (+0.44%) ▲|GEV1,152.23+39.12 (+3.51%) ▲|GILD129.61-1.66 (-1.26%) ▼|GM77.86+1.86 (+2.45%) ▲|GOOG364.90+8.72 (+2.45%) ▲|GOOGL366.46+6.55 (+1.82%) ▲|GS1,055.07+34.07 (+3.34%) ▲|HD350.66-7.24 (-2.02%) ▼|HON231.18+1.32 (+0.57%) ▲|IBM299.49+9.97 (+3.44%) ▲|INTC122.20+1.85 (+1.54%) ▲|INTU272.14-3.21 (-1.17%) ▼|ISRG432.83+6.82 (+1.60%) ▲|JNJ259.29-3.75 (-1.43%) ▼|JPM337.87+4.90 (+1.47%) ▲|KO82.97-1.18 (-1.40%) ▼|LIN540.52-6.12 (-1.12%) ▼|LLY1,202.56-11.35 (-0.94%) ▼|LMT537.70-8.21 (-1.50%) ▼|LOW223.77-3.73 (-1.64%) ▼|LRCX350.20-1.21 (-0.34%) ▼|MA533.20-6.20 (-1.15%) ▼|MCD279.47-1.16 (-0.41%) ▼|MDLZ59.17-1.74 (-2.86%) ▼|MDT83.06-0.13 (-0.16%) ▼|META600.29+17.39 (+2.98%) ▲|MMM159.16-1.28 (-0.80%) ▼|MO71.89-0.83 (-1.13%) ▼|MRK126.79-2.77 (-2.14%) ▼|MS222.08+8.15 (+3.81%) ▲|MSFT386.74-3.75 (-0.96%) ▼|MU984.75+9.19 (+0.94%) ▲|NEE87.48-0.86 (-0.97%) ▼|NFLX76.02-1.63 (-2.10%) ▼|NKE43.34-0.76 (-1.71%) ▼|NOW107.91+1.59 (+1.50%) ▲|NVDA195.55+0.72 (+0.37%) ▲|ORCL143.79+3.52 (+2.51%) ▲|PEP143.29-0.93 (-0.64%) ▼|PFE23.73-0.59 (-2.43%) ▼|PG149.31-2.10 (-1.39%) ▼|PLTR132.54+3.24 (+2.51%) ▲|PM184.76+2.49 (+1.37%) ▲|QCOM186.48+10.23 (+5.80%) ▲|RTX201.38+2.13 (+1.07%) ▲|SBUX102.11-2.16 (-2.07%) ▼|SCHW100.61+3.61 (+3.72%) ▲|SO96.00-1.98 (-2.02%) ▼|SPG224.99-1.07 (-0.47%) ▼|T20.59+0.01 (+0.02%) ▲|TMO517.55-5.89 (-1.13%) ▼|TMUS181.79+4.27 (+2.41%) ▲|TSLA419.77+26.32 (+6.69%) ▲|TXN303.50+10.42 (+3.56%) ▲|UBER72.43-2.00 (-2.69%) ▼|UNH418.20-7.16 (-1.68%) ▼|UNP282.58+0.33 (+0.12%) ▲|UPS110.02-0.65 (-0.58%) ▼|USB62.84+1.11 (+1.79%) ▲|V357.23-4.90 (-1.35%) ▼|VZ42.08-0.48 (-1.13%) ▼|WFC87.46+1.95 (+2.28%) ▲|WMT110.65-1.19 (-1.06%) ▼|XOM136.50-0.59 (-0.43%) ▼|
19.4 C
New York
Monday, July 6, 2026

Tag: as

newssourceFORcompanyinformationcontent1releasesmarket

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Cyndee Haydon Named Among 2026 Best Real Estate Agents in the United States by RealTrends, Ranking #723 in Florida Out of 232,000 Realtors

Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data 
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data

Are AI Crypto Trading Bots Suitable for Crypto Beginners? BulkQuant Launches an Automated Crypto Trading App

BulkQuant introduces an automated crypto trading app designed to help beginners access AI crypto trading bots with a simpler workflow, reduced manual operation, and clearer automation features. 
BulkQuant introduces an automated crypto trading app designed to help beginners access AI crypto trading bots with a simpler workflow, reduced manual operation, and clearer automation features.

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

TEAMEX Delivers First EV-Drill LANCE in the United States to Pennsylvania Fire Department

FAIRFIELD, N.J., June 6, 2026 /PRNewswire/ -- TEAMEX Corp, the exclusive North American distributor of TANKTECH Co., Ltd., announced the first U.S. deployment of the...

ThinkCareBelieve: Week 72 of the Trump 2.0 Administration

Week 72 of the Trump Administration was filled with accomplishments. This week marked Day 500 of President Trump’s Presidency.

In HelloNation, Periodontics Expert Dr. Scott Kissel of Manhattan, NY, Details Why Microsurgical Techniques Matter in Periodontal Care

The article explains how precision-focused periodontal procedures can support tissue preservation, improve healing, and patient comfort.MANHATTAN, N.Y., June 6, 2026 /PRNewswire/ -- Why is...

PureHealth Research Highlights Growing Consumer Interest in Lymphatic Wellness and Botanical Support

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today highlighted the growing consumer interest in lymphatic wellness and the role botanicals may play...

Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today pointed to the growing scientific interest in naturally sourced peptide nutrition for healthy aging...

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAs

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers